|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GATA4 |
Gene summary for GATA4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GATA4 | Gene ID | 2626 |
| Gene name | GATA binding protein 4 | |
| Gene Alias | ASD2 | |
| Cytomap | 8p23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B3KUF4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2626 | GATA4 | Pat01-B | Human | Stomach | GC | 2.83e-13 | 3.85e-01 | 0.5754 |
| 2626 | GATA4 | Pat02-B | Human | Stomach | GC | 1.44e-19 | 2.48e-01 | 0.0368 |
| 2626 | GATA4 | Pat03-B | Human | Stomach | GC | 4.80e-15 | 3.56e-01 | 0.3693 |
| 2626 | GATA4 | Pat04-B | Human | Stomach | GC | 1.08e-27 | 5.78e-01 | -0.1483 |
| 2626 | GATA4 | Pat05-B | Human | Stomach | GC | 2.20e-07 | 3.63e-01 | -0.0353 |
| 2626 | GATA4 | Pat06-B | Human | Stomach | GC | 1.57e-27 | 4.21e-01 | -0.1961 |
| 2626 | GATA4 | Pat07-B | Human | Stomach | GC | 7.41e-03 | 3.92e-01 | 0.0935 |
| 2626 | GATA4 | Pat09-B | Human | Stomach | GC | 2.57e-05 | 2.83e-01 | -0.0359 |
| 2626 | GATA4 | Pat11-B | Human | Stomach | GC | 1.57e-22 | 5.33e-01 | -0.182 |
| 2626 | GATA4 | Pat12-B | Human | Stomach | GC | 1.05e-04 | 1.13e-01 | 0.0325 |
| 2626 | GATA4 | Pat13-B | Human | Stomach | GC | 3.18e-06 | 3.17e-01 | 0.0555 |
| 2626 | GATA4 | Pat15-B | Human | Stomach | GC | 4.70e-10 | 3.68e-01 | -0.0778 |
| 2626 | GATA4 | Pat18-B | Human | Stomach | GC | 1.94e-13 | 2.95e-01 | -0.0432 |
| 2626 | GATA4 | Pat19-B | Human | Stomach | GC | 1.23e-07 | 3.21e-01 | 0.0826 |
| 2626 | GATA4 | Pat22-B | Human | Stomach | GC | 8.63e-32 | 5.06e-01 | -0.1042 |
| 2626 | GATA4 | Pat24-B | Human | Stomach | GC | 3.19e-05 | 2.67e-01 | -0.1184 |
| 2626 | GATA4 | Pat25-A | Human | Stomach | CAG with IM | 1.24e-26 | 4.03e-01 | -0.1648 |
| 2626 | GATA4 | Pat26-A | Human | Stomach | CSG | 2.92e-26 | 3.58e-01 | -0.2402 |
| 2626 | GATA4 | Pat28-A | Human | Stomach | CSG | 2.96e-11 | 3.03e-01 | -0.2594 |
| 2626 | GATA4 | Pat29-A | Human | Stomach | CAG with IM | 5.43e-04 | 3.16e-01 | -0.2769 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206021 | Stomach | CSG | wound healing | 49/1034 | 422/18723 | 7.12e-07 | 3.77e-05 | 49 |
| GO:003428421 | Stomach | CSG | response to monosaccharide | 31/1034 | 225/18723 | 2.46e-06 | 1.09e-04 | 31 |
| GO:000974321 | Stomach | CSG | response to carbohydrate | 33/1034 | 253/18723 | 3.99e-06 | 1.63e-04 | 33 |
| GO:003459921 | Stomach | CSG | cellular response to oxidative stress | 36/1034 | 288/18723 | 3.99e-06 | 1.63e-04 | 36 |
| GO:000974621 | Stomach | CSG | response to hexose | 30/1034 | 219/18723 | 4.01e-06 | 1.63e-04 | 30 |
| GO:000974921 | Stomach | CSG | response to glucose | 28/1034 | 212/18723 | 1.66e-05 | 5.15e-04 | 28 |
| GO:003166721 | Stomach | CSG | response to nutrient levels | 49/1034 | 474/18723 | 1.83e-05 | 5.57e-04 | 49 |
| GO:003004821 | Stomach | CSG | actin filament-based movement | 20/1034 | 127/18723 | 2.09e-05 | 6.18e-04 | 20 |
| GO:190320121 | Stomach | CSG | regulation of oxidative stress-induced cell death | 14/1034 | 74/18723 | 4.58e-05 | 1.19e-03 | 14 |
| GO:007133321 | Stomach | CSG | cellular response to glucose stimulus | 21/1034 | 151/18723 | 8.68e-05 | 2.03e-03 | 21 |
| GO:004259321 | Stomach | CSG | glucose homeostasis | 30/1034 | 258/18723 | 9.62e-05 | 2.18e-03 | 30 |
| GO:190040721 | Stomach | CSG | regulation of cellular response to oxidative stress | 15/1034 | 89/18723 | 9.99e-05 | 2.22e-03 | 15 |
| GO:003350021 | Stomach | CSG | carbohydrate homeostasis | 30/1034 | 259/18723 | 1.03e-04 | 2.28e-03 | 30 |
| GO:007133121 | Stomach | CSG | cellular response to hexose stimulus | 21/1034 | 153/18723 | 1.05e-04 | 2.29e-03 | 21 |
| GO:007132621 | Stomach | CSG | cellular response to monosaccharide stimulus | 21/1034 | 154/18723 | 1.15e-04 | 2.47e-03 | 21 |
| GO:003647321 | Stomach | CSG | cell death in response to oxidative stress | 15/1034 | 95/18723 | 2.12e-04 | 4.04e-03 | 15 |
| GO:007132221 | Stomach | CSG | cellular response to carbohydrate stimulus | 21/1034 | 163/18723 | 2.58e-04 | 4.69e-03 | 21 |
| GO:003133021 | Stomach | CSG | negative regulation of cellular catabolic process | 29/1034 | 262/18723 | 2.92e-04 | 5.07e-03 | 29 |
| GO:190288221 | Stomach | CSG | regulation of response to oxidative stress | 15/1034 | 98/18723 | 3.01e-04 | 5.17e-03 | 15 |
| GO:000167821 | Stomach | CSG | cellular glucose homeostasis | 21/1034 | 172/18723 | 5.37e-04 | 8.02e-03 | 21 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0453012 | Stomach | GC | Tight junction | 33/708 | 169/8465 | 3.03e-06 | 4.65e-05 | 3.28e-05 | 33 |
| hsa042186 | Stomach | GC | Cellular senescence | 25/708 | 156/8465 | 1.13e-03 | 7.72e-03 | 5.43e-03 | 25 |
| hsa0453013 | Stomach | GC | Tight junction | 33/708 | 169/8465 | 3.03e-06 | 4.65e-05 | 3.28e-05 | 33 |
| hsa0421811 | Stomach | GC | Cellular senescence | 25/708 | 156/8465 | 1.13e-03 | 7.72e-03 | 5.43e-03 | 25 |
| hsa0453021 | Stomach | CAG with IM | Tight junction | 32/640 | 169/8465 | 9.69e-07 | 1.62e-05 | 1.14e-05 | 32 |
| hsa0421821 | Stomach | CAG with IM | Cellular senescence | 24/640 | 156/8465 | 6.19e-04 | 5.05e-03 | 3.54e-03 | 24 |
| hsa0453031 | Stomach | CAG with IM | Tight junction | 32/640 | 169/8465 | 9.69e-07 | 1.62e-05 | 1.14e-05 | 32 |
| hsa0421831 | Stomach | CAG with IM | Cellular senescence | 24/640 | 156/8465 | 6.19e-04 | 5.05e-03 | 3.54e-03 | 24 |
| hsa0453041 | Stomach | CSG | Tight junction | 31/633 | 169/8465 | 2.29e-06 | 3.45e-05 | 2.48e-05 | 31 |
| hsa0421841 | Stomach | CSG | Cellular senescence | 24/633 | 156/8465 | 5.29e-04 | 4.18e-03 | 3.00e-03 | 24 |
| hsa0453051 | Stomach | CSG | Tight junction | 31/633 | 169/8465 | 2.29e-06 | 3.45e-05 | 2.48e-05 | 31 |
| hsa0421851 | Stomach | CSG | Cellular senescence | 24/633 | 156/8465 | 5.29e-04 | 4.18e-03 | 3.00e-03 | 24 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| GATA4 | STM | Pancreas | ADJ | C5,RBPJL,MECOM, etc. | 2.34e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GATA4 | SNV | Missense_Mutation | novel | c.649N>C | p.Glu217Gln | p.E217Q | P43694 | protein_coding | deleterious(0) | possibly_damaging(0.559) | TCGA-OL-A66I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| GATA4 | SNV | Missense_Mutation | c.701N>T | p.Thr234Met | p.T234M | P43694 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GATA4 | SNV | Missense_Mutation | rs745533633 | c.797G>A | p.Arg266His | p.R266H | P43694 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
| GATA4 | SNV | Missense_Mutation | rs781198110 | c.1100N>T | p.Thr367Met | p.T367M | P43694 | protein_coding | deleterious(0) | possibly_damaging(0.77) | TCGA-CK-4950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folfox | SD |
| GATA4 | SNV | Missense_Mutation | rs145999237 | c.1087N>T | p.Arg363Cys | p.R363C | P43694 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| GATA4 | SNV | Missense_Mutation | rs376885265 | c.1166N>T | p.Ala389Val | p.A389V | P43694 | protein_coding | tolerated(0.31) | benign(0.01) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| GATA4 | SNV | Missense_Mutation | c.727G>A | p.Gly243Ser | p.G243S | P43694 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| GATA4 | SNV | Missense_Mutation | rs200167770 | c.1067N>G | p.Thr356Ser | p.T356S | P43694 | protein_coding | tolerated(0.53) | benign(0) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GATA4 | SNV | Missense_Mutation | novel | c.1157N>T | p.Ser386Leu | p.S386L | P43694 | protein_coding | deleterious(0.04) | benign(0) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| GATA4 | SNV | Missense_Mutation | rs759067821 | c.1151N>T | p.Thr384Met | p.T384M | P43694 | protein_coding | deleterious(0.03) | possibly_damaging(0.451) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | NSC-85661 | CHEMBL1684098 | 21310620 | |
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | Drugs used in alcohol dependence | 20585342 | ||
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | ANTHRACYCLINES | 12527808 | ||
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | warfarin | WARFARIN | 25026456,29298995 | |
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | NSC-140905 | CHEMBL1684097 | 21310620 | |
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | NSC-126866 | CHEMBL1684099 | 21310620 | |
| 2626 | GATA4 | TRANSCRIPTION FACTOR, ENZYME, CLINICALLY ACTIONABLE | RIBAVIRIN MONOPHOSPHATE | RIBAVIRIN MONOPHOSPHATE | 21310620 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |